59 / 67
CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 2, March 2013
AFRICA
e9
contribute to
in situ
thrombosis. It is therefore difficult to make
a distinction between causative factors. In patients with arterial
thrombus we should not only change the chemotherapeutic
regimen but also put them on a strong anticoagulant in order to
prevent future thrombotic events.
References
1.
Bick RL. Cancer-associated thrombosis.
N Engl J Med
2003;
349
:
109–111.
2.
Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ,
Prins MH. Symptomatic venous thromboembolism in cancer patients
treated with chemotherapy: an underestimated phenomenon.
Arch
Intern Med
2004;
164
: 190–194.
3.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies,
prothrombotic mutations, and the risk of venous thrombosis.
J Am Med
Assoc
2005;
293
: 715–722.
4.
Theodossiou C, Kroog G, Ettinghausen S, Tolcher A, Cowan K,
O’Shaughnessy J. Acute arterial thrombosis in a patient with breast
cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin,
cyclophosphamide, and interleukin-3.
Cancer
1994;
74
: 2808–2810.
5.
Tsang JS, Naughton PA, O’Donnell J, Wang TT, Moneley DS, Kelly CJ,
Leahy AL. Acute limb ischemia in cancer patients: should we surgically
intervene?
Ann Vasc Surg
2011;
25
: 954–960.
6.
Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and
angiogenesis in cancer-associated venous thromboembolism.
J Clin
Oncol
2003;
21
: 4194–4199.
7.
El Sakka K, Gambhir RP, Halawa M, Chong P, Rashid H. Association
of malignant disease with critical leg ischaemia.
Br J Surg
2005;
92
:
1498–1501.
8.
Heinrich N, Born M, Hoebert E, Verrel F, SimonA, Bode U, Fleischhack
G. Aortobifemoral embolism in an 18-year old patient following cis-
platin and 5-fluorouracil chemotheraphy for nasopharyngeal carci-
noma.
Vasa
2010;
39
: 271–273.
9.
Lesterhuis WJ, van Spronsen DJ, Schultze-Kool LJ, de Mulder PH.
Acute arterial occlusion after chemotherapy for testicular cancer.
Lancet Oncol
2005;
6
: 910.